Until recently, an injection of immune globulin (IG) was the only recommended way to protect people after they have been exposed to hepatitis A virus. In June 2007, U.S. guidelines were revised to allow for hepatitis A vaccine to be used after exposure to prevent infection in healthy persons aged 1–40 years. Persons who recently have been exposed to hepatitis A virus (HAV) and who previously have not received hepatitis A vaccine should be administered a single dose of single-antigen vaccine or immunoglobulin (IG) (0.02 mL/kg) as soon as possible.  Information about the relative efficacy of vaccine compared with immunoglobulin postexposure is limited, and no data are available for persons aged more than 40 years or those with underlying medical conditions.  Therefore, decisions to use vaccine or immunoglobulin should take into account patient characteristics associated with more severe manifestations of hepatitis A, including older age and chronic liver disease.
Hepatitis A secondary prevention
Hepatitis E primary prevention
Hepatitis C secondary prevention
Hepatitis A primary prevention
Hepatitis B secondary prevention
Hepatitis C primary prevention
Hepatitis B primary prevention
Hepatitis B future or investigational therapies